The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Larson, Richard A.
One or more keywords matched the following items that are connected to Larson, Richard A.
Item TypeName
Concept Protein Kinase Inhibitors
Academic Article Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Academic Article Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML.
Academic Article Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Academic Article Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Academic Article Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Academic Article Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
Academic Article A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Academic Article Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Academic Article Adult ALL: where are we and where are we going?
Academic Article Current practices in the management of chronic myeloid leukemia.
Academic Article Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Academic Article Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Academic Article A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Academic Article BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Academic Article Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Academic Article Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Academic Article Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
Academic Article Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
Academic Article Is there a best TKI for chronic phase CML?
Academic Article Is there a best TKI for chronic phase CML?
Academic Article Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Academic Article Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Academic Article Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Academic Article Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Academic Article Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Academic Article Imatinib is still recommended for frontline therapy for CML.
Academic Article Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Academic Article European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Academic Article Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Academic Article Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Academic Article Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
Academic Article Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.
Academic Article Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Academic Article Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
Academic Article Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Academic Article Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Academic Article Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Academic Article Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
Search Criteria
  • Protein Kinase Inhibitors